GlobalResearch and clinical trials
Venglustat phase 3 in late-onset Tay-Sachs and Sandhoff disease: no clinical benefit seen
In the phase 3 trial, 40 adults received venglustat and 19 adults received placebo.
Lysosomal storage diseases
An inherited disease that gradually damages the nerve cells in the brain and spinal cord. It most often begins in infancy. It is very similar to Tay-Sachs disease.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
Orphanet has a guideline for emergency doctors for this disease (language: French). See on Orphanet
This page is translated from the Turkish original.
This disease is followed through the “Lysosomal storage diseases” group.
Two enzymes in the cells, hexosaminidase A and B, do not work well. Because of this, a fatty substance called GM2 cannot be broken down. The substance builds up in the nerve cells. Over time, the nerve cells in the brain and spinal cord are damaged.
The most common form begins in infancy. Babies look normal until 3–6 months. There are also very rare, milder forms that begin in childhood or adulthood.
The doctor looks at the symptoms and the eye examination. The activity of the enzymes hexosaminidase A and B is measured in the blood. The diagnosis is confirmed with a genetic test.
At present, there is no approved treatment specific to the disease. Care aims to ease the symptoms. Nutrition and fluid support, keeping the airway open and seizure treatment are important. New methods such as gene therapy are being researched. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Diseases of this kind may be more common in marriages between relatives. Genetic counselling is recommended.
Source: MedlinePlus Genetics: Sandhoff disease · NORD: Sandhoff Disease · Orphanet: Sandhoff disease (ORPHA:796)
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
For all rare diseases: Nadir Hastalıklar Federasyonu
Links checked on October 8, 2026.
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
GlobalResearch and clinical trials
In the phase 3 trial, 40 adults received venglustat and 19 adults received placebo.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 2 active interventional studies for this disease. 1 is recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Early stage: safety and dose are being tested · Phase 1 · investigational (experimental)RecruitingNCT02254863
Middle stage: the effect is being tested in a small group · Phase 2 · investigational (experimental)Not yet recruitingNCT07740512
See all studies on ClinicalTrials.gov · Joining clinical trials
InternationalResearch and clinical trials
Records of 19 sibling pairs with Hunter syndrome were compared.
USANew treatments and approvals
The FDA has approved rebisufligene etisparvovec for children with Sanfilippo syndrome type A (MPS IIIA).
ChinaResearch and clinical trials
In China, 6 children with infantile-onset Pompe disease were given a single dose of gene therapy.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:796
No separate ICD-11 code; WHO classifies this disease under: 5C56.00
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.